SGH
Sivik Global Healthcare Portfolio holdings
AUM
$224M
This Quarter Return
+10.43%
1 Year Return
+5.3%
3 Year Return
+45.33%
5 Year Return
+103.79%
10 Year Return
+430.94%
AUM
$260M
AUM Growth
+$260M
(+21%)
Cap. Flow
+$28.4M
Cap. Flow
% of AUM
10.91%
Top 10 Holdings %
Top 10 Hldgs %
28.77%
Holding
78
New
17
Increased
25
Reduced
14
Closed
14
Top Buys
| 1 |
Eli Lilly
LLY
|
$6.83M |
| 2 |
Merck
MRK
|
$6.45M |
| 3 |
AstraZeneca
AZN
|
$5.27M |
| 4 |
Cencora
COR
|
$4.9M |
| 5 |
Cigna
CI
|
$4.25M |
Top Sells
| 1 |
AbbVie
ABBV
|
$7.1M |
| 2 |
Universal Health Services
UHS
|
$6.51M |
| 3 |
Cardinal Health
CAH
|
$5.01M |
| 4 |
Smith & Nephew
SNN
|
$3.82M |
| 5 |
UnitedHealth
UNH
|
$3.54M |
Sector Composition
| 1 | Healthcare | 93.84% |
| 2 | Energy | 1.15% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Fresenius Medical Care
FMS
$15.1B
| $1.76M | 0.68% |
35,000
-15,000
| -30% | -$755K |
|
|
ENDP
52
DELISTED
Endo International plc
ENDP
| $1.7M | 0.65% |
+180,000
| New | +$1.7M |
|
|
AKRX
53
DELISTED
Akorn, Inc.
AKRX
| $1.66M | 0.64% |
100,000
+9,901
| +11% | +$164K |
|
|
ONCE
54
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $1.66M | 0.64% |
+20,000
| New | +$1.66M |
|
|
XENT
55
DELISTED
Intersect ENT, Inc
XENT
| $1.61M | 0.62% |
43,000
-22,000
| -34% | -$824K |
|
56
Coherus Oncology, Inc. Common Stock
CHRS
$135M
| $1.4M | 0.54% |
+100,000
| New | +$1.4M |
|
|
NVRO
57
DELISTED
NEVRO CORP.
NVRO
| $1.28M | 0.49% |
16,002
-18,998
| -54% | -$1.52M |
|
58
Puma Biotechnology
PBYI
$254M
| $1.18M | 0.45% |
20,000
-5,000
| -20% | -$296K |
|
59
DexCom
DXCM
$29.5B
| $1.04M | 0.4% |
+10,900
| New | +$1.04M |
|
60
Acadia Pharmaceuticals
ACAD
$4.38B
| $723K | 0.28% |
+47,351
| New | +$723K |
|
|
PTLA
61
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $567K | 0.22% |
+15,000
| New | +$567K |
|
|
62
AbbVie
ABBV
$372B
| – | – |
-75,000
| Closed | -$7.1M |
|
63
Becton Dickinson
BDX
$55.3B
| – | – |
-10,000
| Closed | -$2.17M |
|
|
BPMC
64
DELISTED
Blueprint Medicines
BPMC
| – | – |
-20,000
| Closed | -$1.83M |
|
|
65
Cardinal Health
CAH
$35.5B
| – | – |
-80,000
| Closed | -$5.01M |
|
66
Chemed
CHE
$6.67B
| – | – |
-7,500
| Closed | -$2.05M |
|
67
Galapagos
GLPG
$2.07B
| – | – |
0
| – | – |
|
68
Haemonetics
HAE
$2.63B
| – | – |
-26,893
| Closed | -$1.97M |
|
69
HCA Healthcare
HCA
$94.5B
| – | – |
-25,000
| Closed | -$2.43M |
|
70
Neurocrine Biosciences
NBIX
$13.8B
| – | – |
-30,000
| Closed | -$2.49M |
|
71
Revvity
RVTY
$10.5B
| – | – |
-45,000
| Closed | -$3.41M |
|
|
72
Smith & Nephew
SNN
$16.3B
| – | – |
-100,000
| Closed | -$3.82M |
|
73
Teladoc Health
TDOC
$1.37B
| – | – |
-40,000
| Closed | -$1.61M |
|
74
Bio-Techne
TECH
$8.5B
| – | – |
-20,000
| Closed | -$3.02M |
|
|
75
Universal Health Services
UHS
$11.6B
| – | – |
-55,000
| Closed | -$6.51M |
|